Financial

Globus Medical Inc (NYSE:GMED) Receives $27.67 Average Target Price from Analysts

by  – May 29, 2016

 

Globus Medical Inc (NYSE:GMED) has been given a consensus rating of “Hold” by the eleven research firms that are presently covering the firm. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $27.67.

A number of analysts have commented on GMED shares. Leerink Swann reissued an “outperform” rating and set a $29.00 price objective (down from $32.00) on shares of Globus Medical in a report on Thursday, February 25th. Canaccord Genuity reissued a “buy” rating and set a $30.00 price objective on shares of Globus Medical in a report on Thursday, February 25th. William Blair reissued an “outperform” rating on shares of Globus Medical in a report on Wednesday, February 24th. Zacks Investment Research lowered Globus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, April 27th. Finally, Oppenheimer reissued a “buy” rating and set a $29.00 price objective on shares of Globus Medical in a report on Wednesday, May 4th.

 

READ THE REST HERE

 

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close
Themed By teapots